US Patent 6,784,177: Claim Scope, Expiration, Orange Book Status, and BiDil Patent Landscape

US Patent 6,784,177 protected methods of administering hydralazine with isosorbide dinitrate or isosorbide mononitrate to Black patients for heart failure, hypertension, mortality reduction, oxygen consumption, exercise tolerance, or quality-of-life benefits. The patent covered both fixed-dose and separately administered products, a broad range of hydralazine compounds, optional background cardiovascular therapies, and oral dosage forms.

The patent was associated with NitroMed’s BiDil development program. Its patent term expired in December 2019, eliminating current US patent exclusivity under the patent. The claims remain relevant for historical validity, infringement, prosecution, Orange Book, and patent-estate analysis, but they do not presently block generic use of the claimed regimen.

What drug and therapeutic regimen does US Patent 6,784,177 protect?

The patent covers combination treatment using:

Hydralazine or a pharmaceutically acceptable salt, principally hydralazine hydrochloride.
Isosorbide dinitrate or isosorbide mononitrate.
A Black patient.
Heart failure, hypertension, mortality reduction, improved oxygen consumption, exercise tolerance, or improved quality of life.

The most commercially important embodiment was hydralazine hydrochloride plus isosorbide dinitrate in the fixed-dose BiDil tablet. BiDil was approved by the FDA in 2005 for the treatment of heart failure in self-identified Black patients as an adjunct to standard therapy. The approved tablet contained 37.5 mg of hydralazine hydrochloride and 20 mg of isosorbide dinitrate per tablet. The labeled initial dose was generally one tablet three times daily, with titration to two tablets three times daily, corresponding to a maximum daily dose of 225 mg hydralazine hydrochloride and 120 mg isosorbide dinitrate.[1]

The patent claims are broader than the approved BiDil label in several respects. They include isosorbide mononitrate, multiple hydralazine analogues, separate-component administration, hypertension, and various dosage forms that were not necessarily part of the approved product.

How many independent claim concepts are contained in the patent?

The 84 claims contain approximately 17 independent claim concepts, with extensive dependent-claim duplication. The principal independent categories are:

Claim group	Therapeutic objective	Active ingredients	Patient limitation
Claims 1-2	Mortality reduction or improved oxygen consumption	Hydralazine plus isosorbide dinitrate	Black patient
Claims 3 and 8	Mortality reduction or oxygen consumption	Hydralazine compound plus isosorbide dinitrate or mononitrate	Black patient
Claims 17 and 22	Mortality reduction or oxygen consumption	Hydralazine plus isosorbide mononitrate	Black patient
Claims 23	Hypertension treatment	Hydralazine compound plus isosorbide dinitrate or mononitrate	Black patient
Claims 41-42	Hypertension treatment	Hydralazine plus dinitrate or mononitrate	Black patient
Claims 43	Exercise tolerance or quality of life	Hydralazine compound plus dinitrate or mononitrate	Black patient
Claims 62-63	Exercise tolerance or quality of life	Hydralazine plus dinitrate or mononitrate	Black patient
Claim 64	Heart failure treatment	Hydralazine compound plus dinitrate or mononitrate	Black patient
Claims 83-84	Heart failure treatment	Hydralazine plus dinitrate or mononitrate	Black patient

The broadest practical claims are claims 3, 8, 23, 43, and 64. Each requires the combination of a hydralazine compound and at least one of isosorbide dinitrate or isosorbide mononitrate. The additional agents are optional and therefore do not create a mandatory multi-drug regimen.

What are the key limitations in the independent claims?

The Black-patient limitation

Every independent claim requires treatment of a “black patient.” This limitation was central to the patent’s differentiation from earlier hydralazine-nitrate heart-failure regimens.

The patent does not require a genetic test, biomarker, ancestry panel, or specific racial classification methodology. The claim language uses a patient-characterization limitation. The FDA label used “self-identified Black patients,” reflecting the enrollment and labeling framework of the African-American Heart Failure Trial, or A-HeFT.[1,2]

In an infringement analysis, the patient limitation creates practical evidentiary issues. A generic product manufacturer generally controls the product, not the prescribing physician’s patient selection. Direct method-of-use liability would depend on the circumstances of prescribing, labeling, promotional conduct, induced infringement, or other proof connecting the accused party to the claimed use.

The combination limitation

The claims require both:

A hydralazine compound or salt; and
Isosorbide dinitrate or isosorbide mononitrate.

Hydralazine alone does not meet the combination requirement. Isosorbide dinitrate or mononitrate alone also does not meet it.

The claims reach administration as:

A single composition.
Separate components.
A fixed-dose oral product.
Separate tablets or capsules administered in the same treatment regimen.

Claims 7, 12, 30, 31, 50, 51, 71, and 72 expressly address same-composition and separate-component administration.

The dosage limitation

The principal dosage ranges are:

Ingredient	Claimed range
Hydralazine or hydralazine salt	About 30 mg/day to about 300 mg/day
Isosorbide dinitrate	About 20 mg/day to about 200 mg/day
Isosorbide mononitrate	About 10 mg/day to about 120 mg/day

The approved BiDil maximum of 225 mg/day hydralazine hydrochloride and 120 mg/day isosorbide dinitrate falls within the claimed hydralazine range and within the isosorbide dinitrate range.

The use of “about” creates a numerical boundary issue. A product or regimen materially outside the stated ranges would present a stronger noninfringement position, although the specification, prosecution history, claim construction, and equivalents analysis would remain relevant.

What hydralazine compounds are covered by US Patent 6,784,177?

Claims 5, 10, 25, 45, and 66 list the following hydralazine compounds:

Budralazine
Cadralazine
Dihydralazine
Endralazine
Hydralazine
Pildralazine
Todralazine
Pharmaceutically acceptable salts of those compounds

Hydralazine hydrochloride is separately recited in claims 6, 11, 26, 46, and 67.

This structure creates a substantial chemical genus around hydralazine treatment. The commercial significance is narrower because BiDil used hydralazine hydrochloride, while several listed analogues were not established commercial components of the approved product.

What formulations and dosage forms are protected?

The patent contains broad formulation and administration limitations, particularly in claims 34-38 and 55-59 and their counterparts in the heart-failure claims.

Covered forms include:

Oral administration.
Solid oral dosage forms.
Tablets.
Capsules.
Sustained-release capsules.
Sublingual tablets.
Sustained-release tablets.
Chewable tablets.
A single combination composition.
Separate dosage forms administered as part of the same treatment.

The claims are primarily method claims rather than composition claims. A tablet is not necessarily infringing merely because it contains hydralazine and an isosorbide compound. Infringement requires performance of the claimed method, including the patient population and therapeutic purpose.

That distinction matters for generic products. A generic hydralazine tablet and a generic isosorbide dinitrate tablet can be sold independently for their approved indications. The patent’s risk historically arose when the products were promoted, labeled, or used together for the claimed Black-patient heart-failure regimen.

When did US Patent 6,784,177 expire?

US Patent 6,784,177 issued on August 31, 2004. Its ordinary US patent term ran through December 2019. The patent is now expired and does not provide current enforceable exclusivity in the United States.[3]

Event	Date or status
Patent issued	August 31, 2004
Commercial product associated with claims	BiDil
FDA approval of BiDil	June 23, 2005
Patent-term endpoint	December 2019
Current status	Expired
Current blocking right	None under US 6,784,177

The expiration date is distinct from FDA regulatory exclusivity. FDA approval and patent protection are separate rights. Any regulatory exclusivity associated with BiDil did not extend the patent term.

What was the Orange Book status of US Patent 6,784,177?

US Patent 6,784,177 was listed in connection with BiDil, NDA 020727. The listing reflected method-of-use protection for the hydralazine and isosorbide dinitrate combination in the labeled patient population and disease setting.[1,4]

The Orange Book listing did not convert the patent into a composition patent covering hydralazine or isosorbide dinitrate generally. Those active ingredients were long-established drugs with substantial pre-existing use. The listed patent was directed to the claimed treatment method and population.

After patent expiration, the listing no longer creates a live patent barrier to an ANDA applicant. A Paragraph IV certification could have been relevant before expiration. After expiration, an applicant could rely on patent expiration rather than maintain a continuing Paragraph IV dispute.

Which companies challenged or could challenge the patent?

The principal commercial target was BiDil, initially developed and commercialized by NitroMed and later associated with other product owners and marketers. The potential generic challengers were manufacturers capable of submitting an ANDA for the fixed-dose hydralazine hydrochloride/isosorbide dinitrate product.

The patent’s method-of-use structure limited the value of a conventional ANDA challenge. A generic applicant could pursue:

A Paragraph III certification if waiting for patent expiration.
A Paragraph IV certification asserting invalidity, unenforceability, or noninfringement.
A section viii statement carving out the patented indication, where FDA labeling and claim scope permitted.
An ANDA for the underlying ingredients without seeking the BiDil indication.

The supplied claim set does not establish that a particular manufacturer filed a Paragraph IV certification, nor does it establish a final judgment invalidating US 6,784,177. The commercially decisive event was patent expiration rather than a known surviving injunction.

What were the main validity risks for the patent?

Prior-art risk

Hydralazine and nitrate combinations were known before the patent. Earlier heart-failure studies, including the Veterans Administration trials, evaluated hydralazine and isosorbide dinitrate in broader heart-failure populations.[5] The patent’s novelty and nonobviousness position therefore depended heavily on the patient-population limitation and the evidence of clinical benefit in Black patients.

The A-HeFT results supplied the principal clinical basis for the claimed population-specific use. The trial reported a significant reduction in mortality, a reduction in first hospitalization for heart failure, and improvement in quality-of-life measures among self-identified Black patients receiving the combination with standard therapy.[2]

Obviousness risk

An invalidity challenge would likely focus on:

Earlier use of hydralazine and nitrates for heart failure.
Known pharmacology of vasodilator combinations.
Whether the Black-patient limitation supplied a nonobvious therapeutic distinction.
Whether the clinical results were unexpected.
Whether the full scope of the claims was enabled across all listed hydralazine analogues, both nitrate forms, dosage ranges, outcomes, and formulations.

Claims directed specifically to hydralazine hydrochloride plus isosorbide dinitrate and the tested heart-failure population were stronger commercially than claims covering untested analogues, isosorbide mononitrate, hypertension, or broad outcome categories.

Written-description and enablement risk

The claims extend beyond the core A-HeFT regimen. They cover:

Multiple hydralazine analogues.
Isosorbide mononitrate.
Hypertension.
Mortality reduction.
Oxygen consumption.
Exercise tolerance.
Quality of life.
Sustained-release and sublingual forms.
Optional background medications.

That breadth creates potential written-description and enablement pressure. A challenger could argue that the clinical evidence supported only a narrower hydralazine hydrochloride/isosorbide dinitrate regimen in Black patients with heart failure, not every listed compound, formulation, disease state, and clinical endpoint.

How does the patent compare with BiDil’s commercial product?

Attribute	US 6,784,177 claims	FDA-approved BiDil
Hydralazine component	Hydralazine and listed analogues	Hydralazine hydrochloride
Nitrate component	Isosorbide dinitrate or mononitrate	Isosorbide dinitrate
Patient population	Black patient	Self-identified Black patients
Main disease claims	Heart failure, hypertension	Heart failure
Dosage forms	Broad oral and solid forms	Fixed-dose tablet
Administration	Same or separate components	Combination tablet
Core clinical evidence	Broad claim language	A-HeFT regimen
Patent status	Expired	No current exclusivity under this patent

The patent was materially broader than the approved product. Its strongest commercial position was the fixed-dose hydralazine hydrochloride/isosorbide dinitrate heart-failure regimen corresponding to BiDil.

Does biosimilar risk apply to US Patent 6,784,177?

No. Biosimilar law does not apply because BiDil is a small-molecule drug, not a biologic licensed under the Public Health Service Act. The relevant competitive pathway was the ANDA process under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

The competitive risks were therefore:

Generic fixed-dose combination products.
Generic hydralazine and isosorbide products used together.
Label carve-outs.
Separate-component prescribing.
Post-expiration substitution and price competition.

What generic launch scenarios exist after expiration?

The main generic launch scenarios were:

Fixed-dose combination launch

A manufacturer could seek approval for a tablet containing hydralazine hydrochloride and isosorbide dinitrate in the BiDil strength. This would create the closest direct competition.

Separate-component substitution

Generic hydralazine hydrochloride and isosorbide dinitrate were already available independently. Physicians could prescribe the two products separately, although pill burden, dosing coordination, adherence, and reimbursement could reduce clinical interchangeability with a fixed-dose tablet.

Indication carve-out

A generic manufacturer could seek approval for indications outside the patented or formerly patented use, depending on FDA labeling requirements and the scope of the Orange Book use code. This route could reduce method-of-use exposure but would not necessarily prevent off-label prescribing.

Isosorbide mononitrate strategy

The claims expressly cover isosorbide mononitrate. A mononitrate-based product would not avoid the expired patent during its term merely by replacing isosorbide dinitrate. After expiration, the distinction becomes clinically and commercially relevant rather than patent-blocking.

What manufacturing and intellectual-property barriers remain?

The expired patent does not create a current manufacturing barrier. Remaining barriers are primarily regulatory and commercial:

Demonstrating pharmaceutical equivalence to the reference product.
Establishing bioequivalence for a fixed-dose combination.
Matching release characteristics if a modified-release product is pursued.
Managing separate active-ingredient manufacturing and quality controls.
Establishing stability for the combination tablet.
Securing supply of both active ingredients.
Competing against low-cost generic individual components.
Differentiating fixed-dose convenience from separate generic prescribing.

Because hydralazine hydrochloride and isosorbide dinitrate are established small molecules, the technical manufacturing barrier is materially lower than for a new chemical entity or biologic.

Key Takeaways

US Patent 6,784,177 covered methods using hydralazine with isosorbide dinitrate or isosorbide mononitrate in Black patients.
The claims addressed heart failure, mortality reduction, hypertension, oxygen consumption, exercise tolerance, and quality of life.
The claims covered fixed-dose products and separate-component administration.
Hydralazine hydrochloride plus isosorbide dinitrate was the principal commercial embodiment corresponding to BiDil.
The patent claimed more broadly than the FDA-approved product, including hydralazine analogues, isosorbide mononitrate, hypertension, and multiple dosage forms.
The patent issued August 31, 2004 and expired in December 2019.
Its Orange Book significance ended with patent expiration.
Biosimilar law is irrelevant because BiDil is a small-molecule drug.
Current competition is based on generic fixed-dose combinations and separate generic hydralazine and nitrate products.
The principal historical validity issues were prior art, obviousness, written description, enablement, and the breadth of the Black-patient and clinical-outcome limitations.

FAQs

Is US Patent 6,784,177 still enforceable?

No. The patent expired in December 2019 and no longer provides a live US exclusionary right.

Does hydralazine alone infringe US Patent 6,784,177?

No. The claims require hydralazine or a hydralazine compound together with isosorbide dinitrate or isosorbide mononitrate.

Does the patent cover every use of BiDil?

No. It covered specified methods involving a Black patient, the claimed active-ingredient combination, and recited therapeutic objectives or conditions. It did not create a composition patent over all BiDil tablets or a general patent over hydralazine and isosorbide dinitrate.

Could a generic company sell hydralazine and isosorbide dinitrate separately?

Yes. The active ingredients were established drugs, and the method patent expired. During the patent term, labeling, promotional conduct, and the intended use could affect infringement exposure.

Was BiDil protected by a biologic exclusivity period?

No. BiDil is a small-molecule product regulated through the NDA and ANDA framework. Biosimilar exclusivity provisions do not apply.

References

U.S. Food and Drug Administration. (2005). BiDil prescribing information, NDA 020727. FDA.
Taylor, A. L., Ziesche, S., Yancy, C., Carson, P., D’Agostino, R., Ferdinand, K., Taylor, M., Adams, K., Sabolinski, M., Worcel, M., & Cohn, J. N. (2004). Combination of isosorbide dinitrate and hydralazine in Blacks with heart failure. New England Journal of Medicine, 351(20), 2049-2057.
United States Patent and Trademark Office. (2004). U.S. Patent No. 6,784,177, Methods of treating cardiovascular disease with hydralazine and isosorbide dinitrate.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
Cohn, J. N., Archibald, D. G., Ziesche, S., Franciosa, J. A., Harston, W. E., Tristani, F. E., Dunkman, W. B., Jacobs, W., Francis, G. S., Flohr, K. H., Goldman, S., Cobb, F., Shah, P., Saunders, R., Fletcher, R. D., Loeb, H., Hill, M., & Sahn, D. J. (1986). Effect of vasodilator therapy on mortality in chronic congestive heart failure. New England Journal of Medicine, 314(24), 1547-1552.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	7365900	⤷ Start Trial
Canada	2383974	⤷ Start Trial
European Patent Office	1212053	⤷ Start Trial
World Intellectual Property Organization (WIPO)	0117528	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 6,784,177

Summary for Patent: 6,784,177